CXCL8 and colorectal cancer: In these settings, IL-8 inhibition appears to reprogram the TME toward immune activation and improve response rates to ICIs, as demonstrated in murine pancreatic and colorectal cancer models [22,90,91] and supported by ongoing trials such as STOPTRAFFIC-1 (NCT04599140) and the MAGIC-8 study (NCT03689699).